KR920012114A - 사람 면역결핍 바이러스(HIV)의 그룹-특이 항원(gaa)의 선택된 펩타이드, 이의 제법 및 용도 - Google Patents

사람 면역결핍 바이러스(HIV)의 그룹-특이 항원(gaa)의 선택된 펩타이드, 이의 제법 및 용도 Download PDF

Info

Publication number
KR920012114A
KR920012114A KR1019910022867A KR910022867A KR920012114A KR 920012114 A KR920012114 A KR 920012114A KR 1019910022867 A KR1019910022867 A KR 1019910022867A KR 910022867 A KR910022867 A KR 910022867A KR 920012114 A KR920012114 A KR 920012114A
Authority
KR
South Korea
Prior art keywords
peptide
hiv
preparation
gaa
group
Prior art date
Application number
KR1019910022867A
Other languages
English (en)
Inventor
니드리크 마티아스
모드톱 주잔느
볼프 한스
Original Assignee
스타인, 부크
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스타인, 부크, 베링베르케 아크티엔게젤샤프트 filed Critical 스타인, 부크
Publication of KR920012114A publication Critical patent/KR920012114A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

내용 없음

Description

사람 면역결핍 바이러스(HIV)의 그룹-특이 항원(gag)의 선택된 펩타이드, 이의 제법 및 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도 내지 제3도는 gag펩타이드에 의한 HIV 바이러스 합성 억제를 나타내는 실험 1 내지 3에 있어 결과를 나타내는 그래프이다.

Claims (8)

  1. 두 개의 펩타이드 서열 NPGLLETSEGCRQ 및 AATLEEMMTA 중 하나 이상을 함유하며 아미노산 50개 이하인 HIV gag 단백질의 펩타이드.
  2. 제1항에 있어서, 펩타이드 P4, P5, P28 또는 P29를 함유하는 펩타이드.
  3. 제1항 또는 2항에 있어서, 두 개의 펩타이드 서열 NPGLLETSEGCRQ 및 AATLEEMMTA가 N 및/또는 C말단에서 7개 이하의 아미노산이 절단되나 각각의 경우 6개 아미노산보다 짧지 않은 펩타이드.
  4. 제1항 내지 제3항 중 어느 한 항에 있어서, 아스파라긴을 글루타민으로, 또는 글루타민을 아스파라긴으로, 프롤린을 하이드록시프롤린으로, 튜신을 이소튜신 또는 노튜류으로, 글루탐산을 아스파르트산으로, 트레오닌을 세린으로 또는 세린을 트레오닌으로, 시스테인을 세린으로, 아르기닌을 라이신으로, 알라닌을 글리신으로 및/또는 메티오닌을 노르튜신으로 치환과 같은 아미노산 치환중 하나 이상이 이루어지는 펩타이드.
  5. 제1항 내지 제4항 중 어느 한 항에 있어서, 약제로서의 펩타이드.
  6. 제1항 내지 제5항 중 어느 한 항에서 청구한 펩타이드 하나 이상을 불활성 비히클과 함께 함유하는 치료적 조성물.
  7. 단백질 화학의 방법으로 제1항 내지 제4항 중 어느 한 항에서 청구한 펩타이드를 제조하는 방법.
  8. AIDS제어를 위한 약제 제조에 있어 제1항 내지 제5항 중 어느 한 항에서 청구한 펩타이드의 용도.
    ※ 참고사항: 최초출원 내용에 의하여 공개되는 것임.
KR1019910022867A 1990-12-14 1991-12-13 사람 면역결핍 바이러스(HIV)의 그룹-특이 항원(gaa)의 선택된 펩타이드, 이의 제법 및 용도 KR920012114A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4039925.7 1990-12-14
DE4039925A DE4039925A1 (de) 1990-12-14 1990-12-14 Ausgewaehlte peptide des gruppenspezifischen antigens (gag) von humanem immundefizienzvirus (hiv), ihre herstellung und verwendung

Publications (1)

Publication Number Publication Date
KR920012114A true KR920012114A (ko) 1992-07-25

Family

ID=6420301

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910022867A KR920012114A (ko) 1990-12-14 1991-12-13 사람 면역결핍 바이러스(HIV)의 그룹-특이 항원(gaa)의 선택된 펩타이드, 이의 제법 및 용도

Country Status (12)

Country Link
US (1) US5612453A (ko)
EP (2) EP0732339B1 (ko)
JP (2) JP3369585B2 (ko)
KR (1) KR920012114A (ko)
AT (2) ATE143974T1 (ko)
AU (1) AU661464B2 (ko)
CA (1) CA2057612C (ko)
DE (3) DE4039925A1 (ko)
DK (2) DK0490383T3 (ko)
ES (2) ES2176363T3 (ko)
IE (1) IE914353A1 (ko)
PT (1) PT99791B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA903492B (en) * 1989-05-15 1991-02-27 Akzo Nv T-lymphotropic retrovirus monoclonal antibodies
US6426412B1 (en) * 1995-12-20 2002-07-30 Subsidiary No. 3, Inc. Nucleic acids encoding human immunodeficiency virus type 1 genetic suppressor elements
GB9703802D0 (en) 1997-02-24 1997-04-16 Kingsman Susan M Anti-hiv peptides and proteins
NO314588B1 (no) 2000-09-04 2003-04-14 Bionor Immuno As HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
US6818392B2 (en) * 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof
EP1855112A1 (en) * 2006-05-10 2007-11-14 Inserm Method for the in vitro screening of compounds inhibiting production of infectious HIV-1 virions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE54757T1 (de) * 1985-02-05 1990-08-15 Us Commerce Verfahren zum nachweis von htlv-iii neutralisierenden antikoerpern in sera.
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
ATE116006T1 (de) * 1985-04-29 1995-01-15 Genetic Systems Corp Synthetische antigene zum nachweis von aids.
NO881151L (no) * 1987-03-27 1988-09-28 Syntello Ab Syntetisk hiv-1-antigen.
CA1339363C (en) * 1987-05-01 1997-08-26 Alan Ray Flesher Monoclonal antibodies to specific antigenic regions of the human immunodeficiency virus and methods for use
EP0356007A3 (en) * 1988-07-22 1991-07-03 Medical Research Council Antigenic determinants
FR2640877A1 (ko) * 1988-12-06 1990-06-29 Centre Nat Rech Scient
AU641375B2 (en) * 1988-12-20 1993-09-23 Clarity Technologies Incorporated Synthetic HIV-like peptides, their compositions and uses
GB8910145D0 (en) * 1989-05-03 1989-06-21 Connaught Lab Synthetic peptides for an hiv-1 vaccine
NZ235538A (en) * 1989-10-12 1992-06-25 Viral Technologies Inc Peptides immunoreactive with antibodies to hiv p17; carrier-bound peptides, vaccines, immunoassay and a method for forming antibody enriched sera
CA2072351A1 (en) * 1990-01-05 1991-07-06 Andrew J. Mcmichael Hiv-1 core protein fragments
SE468168B (sv) * 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov

Also Published As

Publication number Publication date
EP0490383A2 (de) 1992-06-17
JP3369585B2 (ja) 2003-01-20
ES2095899T3 (es) 1997-03-01
JPH06107697A (ja) 1994-04-19
DE59108261D1 (de) 1996-11-14
CA2057612C (en) 2002-02-05
PT99791B (pt) 1999-05-31
DE4039925A1 (de) 1992-06-17
EP0490383B1 (de) 1996-10-09
ATE216706T1 (de) 2002-05-15
DK0490383T3 (da) 1997-02-17
DE59109235D1 (de) 2002-05-29
AU8976691A (en) 1992-06-18
EP0732339B1 (de) 2002-04-24
DK0732339T3 (da) 2002-08-19
ATE143974T1 (de) 1996-10-15
EP0732339A1 (de) 1996-09-18
US5612453A (en) 1997-03-18
PT99791A (pt) 1992-12-31
EP0490383A3 (en) 1993-06-30
ES2176363T3 (es) 2002-12-01
IE914353A1 (en) 1992-06-17
AU661464B2 (en) 1995-07-27
JP2003176299A (ja) 2003-06-24
CA2057612A1 (en) 1992-06-15

Similar Documents

Publication Publication Date Title
DE60125751D1 (de) Zusammensetzungen und verfahren zur behinderung der vervielfältigung von hiv-1
DK0754704T3 (da) Syntetiske antigener til påvisning af antistoffer mod hepatitis c-virus
DK0792287T3 (da) Peptidanaloger af humant basisk myelinprotein
AU8700291A (en) Hcv-specific peptides, agents therefor and the use thereof
PT725824E (pt) Epitopos de celulas t humanas imunodominantes do virus da hepatite c
DE68927379T2 (de) Plättchen blockierende peptide
EA200000685A1 (ru) Комплекс ifnar2/ifn
ATE185148T1 (de) Lipopeptide, t-cytotoxische lymphocyte aktivierend, und deren verwendung als vakzine
DK1501936T3 (da) Familie af cytokin-proteiner
KR920012114A (ko) 사람 면역결핍 바이러스(HIV)의 그룹-특이 항원(gaa)의 선택된 펩타이드, 이의 제법 및 용도
ATE177843T1 (de) Peptomere mit erhöhter immunogenizität
ATE135407T1 (de) Peptide, welche hiv-retroviren-hemmende antikörper induzieren, sowie gegen diese peptide gerichtete antikörper
EP0361956A3 (en) Increased expression of small molecular weight recombinant proteins
ATE177753T1 (de) Kurze peptide mit insulinwirkung
GB2336844A (en) Anti-hiv peptides and proteins
DK0426314T3 (da) HIV-relaterede peptider
KR970032887A (ko) C형 간염 바이러스에 대한 인체 면역조절기능을 가진 펩타이드
SG145521A1 (en) Synthetic antigens for the detection of antibodies to hepatitis c virus
SE7706567L (sv) Biologiskt aktiva peptider

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E601 Decision to refuse application